Compounds > riopan
Page last updated: 2024-07-31 21:04:06

riopan

Description

Cross-References

ID SourceID
PubMed CID3086011
MeSH IDM0066635

Synonyms (19)

Synonym
riopan plus
magaldrate
aluminum magnesium hydroxide sulfate, hydrate
pentaaluminium-decamagnesium-hentriacontahydroxid-bis(sufat)-n-wasser
ay 5710
unii-6v88e24n5t
riopan
dynese
agastrin
magaldratum
malumix
bemolan
magaldrato
magaldratum [latin]
magaldrato [spanish]
aluminum magnesium hydroxide sulfate (al5mg10(oh)31(so4)2.xh2o)
magaldrate [usan:usp:inn:ban]
Q419991
aluminum;magnesium;hydroxide;sulfate

Research

Studies (51)

TimeframeStudies, This Drug (%)All Drugs %
pre-199028 (54.90)18.7374
1990's15 (29.41)18.2507
2000's6 (11.76)29.6817
2010's1 (1.96)24.3611
2020's1 (1.96)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials12 (21.82%)5.53%
Reviews3 (5.45%)6.00%
Case Studies2 (3.64%)4.05%
Observational0 (0.00%)0.25%
Other38 (69.09%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
hydrochloric acid
2
chlorine molecular entity;
gas molecular entity;
hydrogen halide;
mononuclear parent hydride		mouse metabolite1985198638.5low020000
aminocaproic acid
1
amino acid zwitterion;
epsilon-amino acid;
omega-amino fatty acid		antifibrinolytic drug;
hematologic agent;
metabolite		1991199133.0low101000
6-acetylaminocaproic acid
1
medium-chain fatty acid1991199133.0low101000
theophylline
3
dimethylxanthineadenosine receptor antagonist;
anti-asthmatic drug;
anti-inflammatory agent;
bronchodilator agent;
drug metabolite;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
fungal metabolite;
human blood serum metabolite;
immunomodulator;
muscle relaxant;
vasodilator agent		1962198348.3low030000
aspirin
3
benzoic acids;
phenyl acetates;
salicylates		anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent		1989200031.0low012000
carvedilol
1
carbazoles;
secondary alcohol;
secondary amino compound		alpha-adrenergic antagonist;
antihypertensive agent;
beta-adrenergic antagonist;
cardiovascular drug;
vasodilator agent		2010201014.0low000100
cimetidine
3
aliphatic sulfide;
guanidines;
imidazoles;
nitrile		adjuvant;
analgesic;
anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor		1983200730.3low111100
ciprofloxacin
1
aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion		antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic		2005200519.0low000100
ethylenediamine
2
alkane-alpha,omega-diamineGABA agonist1982198341.5low020000
famotidine
1
1,3-thiazoles;
guanidines;
sulfonamide		anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor		1994199430.0low001000
hydroxyzine
1
hydroxyether;
monochlorobenzenes;
N-alkylpiperazine		anticoronaviral agent;
antipruritic drug;
anxiolytic drug;
dermatologic drug;
H1-receptor antagonist		1962196262.0low010000
indomethacin
4
aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic		1989201027.5low012100
norfloxacin
1
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug;
DNA synthesis inhibitor;
environmental contaminant;
xenobiotic		1996199628.0low001000
omeprazole
1
aromatic ether;
benzimidazoles;
pyridines;
sulfoxide		1994199430.0low001000
pirenzepine
1
pyridobenzodiazepineanti-ulcer drug;
antispasmodic drug;
muscarinic antagonist		1994199430.0low001000
glutamine
1
amino acid zwitterion;
glutamine family amino acid;
glutamine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite		1991199133.0low101000
cysteamine
2
amine;
thiol		geroprotector;
human metabolite;
mouse metabolite;
radiation protective agent		1989199034.5low011000
ephedrine
1
phenethylamine alkaloid;
phenylethanolamines		bacterial metabolite;
environmental contaminant;
nasal decongestant;
plant metabolite;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic		1962196262.0low010000
aminophylline
1
mixturebronchodilator agent;
cardiotonic drug		1982198242.0low010000
limestone
2
calcium salt;
carbonate salt;
inorganic calcium salt;
one-carbon compound		antacid;
fertilizer;
food colouring;
food firming agent		2005200718.0low100200
magnesium carbonate
1
carbonate salt;
magnesium salt;
one-carbon compound;
organic magnesium salt		antacid;
fertilizer		2005200519.0low000100
glycopyrrolate
1
organic bromide salt;
quaternary ammonium salt		1978197846.0low010000
carbonates
3
carbon oxoanion1993200725.3low102100
technetium
1
manganese group element atom1991199133.0low001000
oxmetidine
1
benzodioxoles;
imidazoles;
pyrimidone		anti-ulcer drug;
H2-receptor antagonist		1984198440.0low010000
glucuronic acid
1
D-glucuronic acidalgal metabolite2006200618.0low100100
atropine
1
1978197846.0low010000
sodium bicarbonate
1
one-carbon compound;
organic sodium salt		antacid;
food anticaking agent		2005200519.0low000100
pyrophosphate
1
diphosphate ion1991199133.0low001000
ranitidine
3
C-nitro compound;
furans;
organic sulfide;
tertiary amino compound		anti-ulcer drug;
drug allergen;
environmental contaminant;
H2-receptor antagonist;
xenobiotic		1986198737.7low230000
gelusil
1
1964196460.0low010000
dinoprostone
1
prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic		1989198935.0low010000
morphine
1
morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound		anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic		1978197846.0low010000
lysophosphatidylcholines
1
1-O-acyl-sn-glycero-3-phosphocholine1981198143.0low010000
magnesium trisilicate
1
2005200519.0low000100
aluminum
8
boron group element atom;
elemental aluminium;
metal atom		1960199341.5medium262000
phosphorus
1
monoatomic phosphorus;
nonmetal atom;
pnictogen		macronutrient1987198737.0low010000
aluminum hydroxide, magnesium hydroxide, drug combination
3
1987199632.7low012000
simethicone
1
1987198737.0low010000
technetium tc 99m pyrophosphate
1
1991199133.0low001000
bismuth tripotassium dicitrate
1
1991199133.0low001000
aceglutamide aluminum
1
glutamine derivative1991199133.0high101000
gastrins
2
1983198440.5low020000
rennie
1
2007200717.0low100100
aluminum magnesium silicate
1
1985198539.0low010000
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Acute Disease0
1
2010201014.0low000100
Acute Kidney Failure0
1
1991199133.0low001000
Acute Kidney Injury0
1
1991199133.0low001000
Alcohol Drinking0
1
1991199133.0low101000
Asthma0
1
1962196262.0low010000
Asthma, Bronchial0
1
1962196262.0low010000
Bezoars0
1
1982198242.0low010000
Carditis0
1
2010201014.0low000100
Chest Pain0
1
2010201014.0low000100
Chronic Kidney Failure0
2
1989199134.0low111000
Critical Illness0
1
1991199133.0low101000
Curling Ulcer0
6
1984199136.0low233000
Disease Models, Animal0
1
1991199133.0low001000
Duodenal Ulcer0
6
1984199136.0low233000
Dyspepsia0
1
1985198539.0low010000
Esophageal Reflux0
2
1964200639.0low110100
Esophagitis, Peptic0
1
1964196460.0low010000
Esophagitis, Reflux0
1
1964196460.0low010000
Gastric Ulcer0
8
1964200036.4low244000
Gastritis0
1
1964196460.0low010000
Gastroduodenal Ulcer0
6
1960200737.2low132100
Gastroesophageal Reflux0
2
1964200639.0low110100
Gastrointestinal Hemorrhage0
2
1989199432.5low111000
Hematochezia0
2
1989199432.5low111000
Hemorrhage, Peptic Ulcer0
3
1991200726.7low102100
Indigestion0
1
1985198539.0low010000
Infant, Premature, Diseases0
1
1982198242.0low010000
Infection, Toxoplasma gondii0
1
2010201014.0low000100
Kidney Diseases0
2
1989199134.0low111000
Kidney Failure, Chronic0
2
1989199134.0low111000
Laryngopharyngeal Reflux0
1
202120213.0low000001
Myocarditis0
1
2010201014.0low000100
Peptic Ulcer0
6
1960200737.2low132100
Pericarditis0
1
2010201014.0low000100
Pleuropericarditis0
1
2010201014.0low000100
Precordial Catch0
1
2010201014.0low000100
Recrudescence0
3
1987199433.3low112000
Regurgitation, Gastric0
1
202120213.0low000001
Stomach Ulcer0
8
1964200036.4low244000
Toxoplasmosis0
1
2010201014.0low000100

Bioavailability (4)

ArticleYear
Bioavailability of a crushed pantoprazole tablet after buffering with sodium hydrogencarbonate or magaldrate relative to the intact enteric coated pantoprazole tablet.
Methods and findings in experimental and clinical pharmacology, , Volume: 23, Issue:1
Effect of antacid magaldrate oral suspension on in-vitro and in-vivo availability of indomethacin in dogs.
Pharmaceutica acta Helvetiae, , Volume: 72, Issue:2		1997
Determination of norfloxacin by fluorescence in the presence of different antacids: quantification of analytical interferences.
Journal of pharmaceutical and biomedical analysis, , Volume: 14, Issue:8-10		1996
Serum aluminium levels of intensive care patients treated with two different antacids for prevention of stress ulceration.
Intensive care medicine, , Volume: 15, Issue:2		1989

Dosage (6)

ArticleYear
In vitro evaluation of magaldrate antacid efficacy in the presence of some drugs and its effect on their dissolution rates: Part I.
Bollettino chimico farmaceutico, , Volume: 135, Issue:11		1996
Formulation of aspirin-magaldrate double-layer tablets: in vitro evaluation and cytoprotective activity in rats.
Bollettino chimico farmaceutico, , Volume: 135, Issue:7
Determination of norfloxacin by fluorescence in the presence of different antacids: quantification of analytical interferences.
Journal of pharmaceutical and biomedical analysis, , Volume: 14, Issue:8-10		1996
Effect of antacid and H2-receptor blocker treatment on gastric endocrine cells.
Scandinavian journal of gastroenterology. Supplement, , Volume: 101		1984
[Antacids--gel or tablet. A randomized, double-blind, placebo-controlled study].
Schweizerische medizinische Wochenschrift, , Jul-20, Volume: 115, Issue:29		1985
[Lattice structure antacids and antacid mixtures].
Zeitschrift fur Gastroenterologie, , Volume: 25 Suppl 3		1987